Now Playing
Feature|Videos|June 23, 2025
Industry Voices on Current Pricing and Reimbursement Models
Leading stakeholders in the industry react to how evolving US policies, payer demands, and vertical integration are reshaping market access strategy, stressing the importance of early planning and the urgency of ensuring that innovative therapies are available and affordable for patients.
Advertisement
Episodes in this series
This Peer Exchange® starts off with an introduction of the panel: Edward Ahn, CEO of MEDIPOST, Inc.; Rob Philo, Founder and CEO of Core Market Access Advisors; and Shana Gunderson Hua, PharmD, Vice President of Value & Access at Petauri Advisors. Moderated by Ed Schoonveld, Value and Access Advisor at Schoonveld Advisory, LLC and columnist for Pharmaceutical Executive, the discussion begins with the panelists reflecting on recent policy changes, including the anticipated Medicare Part D updates, and clinical trial design that satisfies FDA requirements and payer expectations.
Key discussion topics include:
- Recent policy changes in the pharmaceutical landscape and what this could mean for payers.
- The current design of trial, pricing, and reimbursement models.
Advertisement
Related to this article
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
3
The Unmet Needs That Will Define the Next Generation of GLP 1s: Q&A with Dr. Bo Liang
4
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
5